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Summary We have previously demonstrated that amiodarone is able to reverse resistance of rat colon cancer
cells to anthracyclines. We now compare the efficiency of amiodarone to verapamil one, another
antiarrhythmic agent used in experimental systems and in clinical trials to enhance the effects of
anthracyclines on resistant cancer cells. Amiodarone is more efficient than verapamil when both drugs are
used at the same molar concentrations. Desethylamiodarone, the main metabolite of amiodarone, is as
efficient as its precursor. Optimal concentrations of amiodarone are obtained without side effects in the sera
of patients treated by oral administration followed by a loading infusion of amiodarone. On the other hand,
maximal tolerated levels of verapamil reported in clinical trials are less efficient than amiodarone maximal
levels in the reversal of resistance to anthracyclines in our experimental model in vitro. We suggest that
amiodarone, which is more efficient and less toxic than verapamil, could be substituted for verapamil in
future clinical trials.
In many experimental tumours, including rat colon cancer,
resistance to anthracyclines is partly attributed to an energy-
dependent efflux of the drugs from the cancer cells
(Skovsgaard, 1975; Inaba et al., 1979). Tsuruo et al. (1982)
first demonstrated that verapamil was able to inhibit this
efflux, so restoring sensitivity to anthracyclines of resistant
cancer cells. We previously reported that amiodarone, a
relatively non toxic antiarrhythmic agent, was able to restore
sensitivity to anthracyclines in naturally resistant rat colon
cancer cells (Chauffert et al., 1986). In the present study, we
demonstrate that amiodarone is more efficient than verapamil
in enhancing the cytotoxic effect of 4'-deoxydoxorubicin
on rat colon cancer cells. We also demonstrate that the effect
of amiodarone on cancer cells is long-lasting and that
efficient plasma concentrations of amiodarone can be
reached in cancer patients without appreciable toxicity.
Materials and methods
Cells and culture conditions
DHD/K12/PRO cell line was established in our laboratory
from a transplantable colon adenocarcinoma induced by 1,2-
dimethylhydrazine in syngeneic BDIX rats (Martin et al.,
1975). DHD/K12/PRO cells exhibit a primary resistance to
anthracyclines due to an active drug efflux (Chauffert et al.,
1984). Cells were cultivated on monolayers in tissue culture
flasks using Ham's FIO medium supplemented with 10%
foetal bovine serum and were detached for experiments by
sequential treatment with EDTA and trypsin.
Drugs
Verapamil (MW491) was obtained from Biosedra
Laboratories (Malakoff, France) and amiodarone (MW681)
from Labaz Laboratories (Bordeaux, France). Desethyl-
amiodarone (MW 652) and L 8040 (used as internal
standard) were gifts from Clin Midy Research Center
(Montpellier, France); 4'deoxydoxorubicin (deoDXR), was a
gift from Farmitalia Laboratories (Milan, Italy). DeoDXR
was selected for this study due to its greater cytotoxicity for
colon cancer cells compared to doxorubicin (Chauffert et al.,
1986).
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Patient sera and amiodarone determinations
Sera were obtained from 3 patients included in a clinical trial
associating amiodarone and anthracyclines for the treatment
of advanced colorectal cancer. Blood samples were collected
after a period of at least 15 days during which the patients
received an oral administration of 400mg amiodarone daily.
The samples were collected before and at the end of a 3 h
infusion of 450mg amiodarone diluted in 250ml of 50gl-1
dextrose solution. Concentrations of amiodarone and its
main metabolite, desethylamiodarone, were determined
according to Pourbaix et al. (1985). Briefly, serum was
extracted twice in a mixture of phosphate buffer (pH 5.4)
and n-hexane in the presence of L 8040 as internal standard.
The organic layer was dried then reconstituted in 200,ul
ethanol; aliquots of this solution were injected in an HPLC
system. The stationary phase was a lichrosorb CN 5jm
column and the mobile phase, an isocratic mixture of
hexane, isopropylic alcohol and sulfuric acid (59.98; 39.98;
0.04). Drugs were detected at 242 nm with a UV detector. In
one patient a sample of serum collected at the end of
amiodarone infusion was also used to assay its enhancing
effect on deoDXR-induced toxicity on rat colon cancer cells
in culture. Normal human serum and serum of the
amiodarone-treated patient were supplemented with 4,M
deoDXR and assayed on tumour target cells as described
above.
Quantitation ofdrug etfects
Studies of [3H]thymidine incorporation were performed by a
previous method (Chauffert et al., 1986). DHD/K12/PRO
cells (1 x 104) were cultivated for 48h in the wells of culture
tissue plates then treated for 1 h with drugs alone or in
combination. After rinsing, cancer cells were incubated for
24 h in [3H]thymidine supplemented culture medium.
Radioactivity of residual cells was measured by a liquid
scintillation counter after lysis by I N NaOH. Eight
microwells were seeded for each determination. Results were
expressed as the percent of inhibition of [3H]thymidine
incoporation in treated cells compared to controls.
Another assay to determine the cytotoxic effect of drugs
or their association was used, according to a previously
described colorimetric test (Martin et al., 1982). Briefly,
DHD/K12/PRO cells were cultivated and treated as in the
former test. After rinsing, cells were cultivated for 72 h in
nutritive medium. At that time, wells were rinsed twice in
Ham's FIO medium in order to remove non adherent dead
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cells. Then, cells were fixed for 10min in absolute ethyl
alcohol and stained with 1% methylene blue in 0.01 M borate
buffer, pH 8.5. After rinsing, the dye bound to residual cells
was eluted with 0.1 N hydrochloric acid and its absorbance
measured on an automatic photometer (Multiskan, Flow
Laboratories, Irvine, UK) equipped with a 630 nm filter.
Absorbance of the eluted dye was demonstrated to be
proportional to the number of residual target cells. Eight
microwells were seeded for each determination. Results were
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Comparison of amiodarone and verapamil enhancement of
deoDXR cytotoxicity was assessed by the Mann Whitney U
test for both assays.
Results
Various concentrations of verapamil or amiodarone were
added to deoDXR at three different concentrations (1, 2 or
3,uM) in order to compare their enhancing effect on
cytotoxicity against rat colon cancer cells. DeoDXR cyto-
toxicity was assayed by inhibition of [3H]thymidine incor-
poration (Figure 1) or by enumeration of surviving cells by a
colorimetric test (Figure 2). Both methods demonstrated a
significant enhancement of deoDXR cytotoxicity on cancer
cells by verapamil or amiodarone. DeoDXR cytotoxicity
depended on deoDXR concentration. In both assays,
amiodarone enhancement of deoDXR cytotoxicity was
greater than verapamil for concentrations beyond 1 yM.
Amiodarone or verapamil without anthracycline had no
cytotoxic effect even at higher concentrations (lO uM)
Desethylamiodarone, the main metabolite of amiodarone,
had the same effect as amiodarone on deoDXR-induced
cytotoxicity (Figure 3). Verapamil and amiodarone also
differed in the duration of their effects on target cells. When
rat colon cancer cells were incubated for 1 h in verapamil or
amiodarone (2 or 8MM) without deoDXR, then washed
before being incubated in deoDXR (4yM) alone for I h,
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Figure 2 Survival of cancer cells after treatment with deoDXR
at different concentrations: 1MM (D], *) 2,uM (0, 0), 3,M
(A, A). Cells were cultivated for 48h then treated for 1 h with
deoDXR associated with verapamil (l, 0, A) or amiodarone
(O, 0, A). After rinsing, cells were reincubated for 72h in
normal nutritive medium then fixed and stained with methylene
blue. Each point is the mean of 8 determinations. Absorbance of
non-treated cells is 100%. (*): significant difference between
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Figure 3 Incorporation of [3H]thymidine into DHD/K12/PRO
cells after a 1 h treatment with 41uM 4'deoxydoxorubicin
(deo DXR) associated with amiodarone (Cl) or desethylamio-
darone (-) at increasing concentrations. The [3H]thymidine
incorporation of non-treated cells is 100%. Each point is the
mean of 4 determinations.
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Figure 1 Incorporation of [3H]thymidine into DIII) K 12/PRO
cells after treatment with 4'deoxydoxorubicin (deoDXR) at
different concentrations: 1MM (I1, *), 2 MM (0, 0) or 3pM (A,
A). Cells were cultivated for 48 h, then treated for 1 h with
deoDXR associated with verapamil (El, 0, A) or amiodarone
(-, 0, A), and reincubated for 24 h in [3H]thymidine
supplemented nutritive medium. Each point is the mean of 8
determinations. Radioactivity of non treated cells was 100%. (*)
indicates a significantly greater enhancement of deoDXR
cytotoxicity by amiodarone compared to verapamil at equimolar
concentration (P<0.05; Mann-Whitney U test).
preliminary exposure of the target cells to amiodarone, but
not by their preliminary exposure to verapamil (Figure 4).
Concentrations of amiodarone and desethylamiodarone in
the sera of patients treated by oral administration of
amiodarone for at least 2 weeks are given in Table I. The
mean sum of amiodarone plus desethylamiodarone concen-
trations was 4.19MM (range: 3.38-5.67,uM) and reached
7.61 ,uM (range: 5.65-8.42MM) after a loading charge
administered by i.v. infusion. When supplemented in vitro
with 4,M deoDXR, serum of a patient treated by oral and
i.v. amiodarone inhibited incorporation of [3H]thymidine in
rat colon cancer cells to a larger extent than serum of an
untreated control (respective inhibitions: 80% and 47%,
P<0.05).
Discussion
In the present study, we demonstrate that at equimolar
concentrations amiodarone is more efficient than verapamil
-
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Table I Amiodarone and desethylamiodarone levels in sera of amiodarone-treated
patients
Serum levels (I.M)
Before i.v. After i.v.
Patient Treatment loading loading
(age, sex, Amiodarone Duration
weight Cycle (days) Amiod. Deamiod. Amiod. Deamiod.
1. (33y, M, 61 kg) 1 23 1.62 1.76 3.81 1.84
2. (66y, F, 59kg) 1 15 2.56 1.07 6.60 0.75
3. (61 y, M, 63 kg) 1 21 2.20 1.53 6.07 2.30
2 42 2.74 1.84 6.31 1.99
3 63 3.53 2.14 6.51 1.91
Serum levels of amiodarone (Amiod.) and desethylamiodarone (Deamiod.) were
compared after oral treatment for 15 days at least with amiodarone (400mgday-1) and
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Figure 4 Incorporation of [3H]thymidine into DHD/K12/PRO
cells after treatment and removal of verapamil and amiodarone
from the incubation medium. Cells were cultivated for 48 h
before a I h incubation in Ham's FIO medium supplemented with
amiodarone (-) or verapamil (0) at 2 or 8pM concentration.
After rinsing twice, cells were then incubated for 1 h in 4pM
deoDXR supplemented culture medium. Persistence of the
enhancement of deoDXR toxicity after removal from the
incubation medium occurred only with amiodarone. Each point
is the mean of 4 determinations. (*) indicates a significant
difference between amiodarone and verapamil assessed by the
Mann-Whitney U test.
in reversing the resistance of rat colon cancer cells to
deoDXR. We also find that desethylamiodarone, the main
metabolite of amiodarone, is as efficient as its precursor.
Furthermore, differing from verapamil, amiodarone induces
a lasting effect on target cells which remains more sensitive
to deoDXR even after extensive washing of amiodarone; this
property of amiodarone is interesting in vitro but not
necessarily in vivo because drug modifiers are usually
administered simultaneously in therapy. We observe in three
patients that serum levels of amiodarone plus desethyl-
amiodarone are above 3,M after oral administration and
reach at least 5.5pM after intravenous amiodarone loading;
clinical cardiovascular symptoms - changes in blood pressure
or electrocardiographic record - were never observed in
these 3 patients during admiodarone administration.
Elevated serum concentrations have also been reported in
patients treated by amiodarone for cardiac arrhythmias.
Andreasen et al. (1981) obtained a mean plasma
concentration of 1.7,M after daily oral administration of
200mg, reaching 14.6pM after an i.v. injection of 400mg.
Mostow et al. (1984) reported that serum concentration
averaged 6.4pM during the loading phase of an i.v. infusion
at the rate of 120mgh-1 amiodarone. These clinically
achievable concentrations are sufficient to obtain a maximal
enhancing effect on anthracycline cytotoxicity in vitro.
Establishment of elevated serum levels of verapamil is
much more limited by the cardiovascular effects of the drug
- atrioventricular conduction block and arterial hypotension
(Singh et al., 1978). Reiter et al. (1982) reported a mean
plasma concentration of 0.27MM in a sustained intravenous
infusion regimen in cardiac patients. In a clinical trial using
infusion of verapamil for enhancing anticancer drug activity,
the reported mean verapamil concentration was 0.62,M
(Benson et al., 1985). However, Rogan et al. (1984) reported
verapamil levels above 3MM, in spite of cardiac cytotoxicity,
in a clinical trial of verapamil-doxorubicin association against
resistant ovarian cancers; at this concentration the maximum
efficacy of verapamil is reached in our in vitro assay;
however, at this concentration, verapamil is less efficient
than amiodarone. Several other phase I trials are on-going
with the goal of enhancing anthracycline efficacy by
verapamil (Benson et al., 1985; Cantwell et al., 1985; Presant
et al., 1984). As amiodarone seems to be less toxic and a
more efficient drug than verapamil in enhancing the effects
of anthracyclines, we suggest that amiodarone, which reaches
efficient plasma concentrations, could be substituted for
verapamil in future clinical trials. However, toxic effects of
amiodarone other than acute cardiac effects, have to be
taken into account. Amiodarone may induce hyperthyroid-
ism, peripheral neuropathy, interstitial pneumonia or
hepatitis in a minority of treated patients (Lubbe et al.,
1982).
The mechanism of the enhancement of anthracycline cyto-
toxicity by amiodarone is likely to be, as in the case of
verapamil, the inhibition of a drug efflux from cancer cells
(Chauffert et al., 1986); however we have also observed that
penetration of drug was of major importance in anthra-
cycline toxicity. So, we used deoxydoxorubicin rather than
doxorubicin due to its better penetration in colon cancer
cells, especially at confluence. The purpose of our further
investigations on resistance to anthracyclines will consider
the both mechanisms; increased efflux and reduced pene-
tration. It will be necessary to study the efficiency of
amiodarone to reverse anthracycline resistance in other
experimental tumour models, including human tumour cell
lines or xenografts in nude mice.
We thank Drs L.C. Ramirez and M.F. Michel for their assistance
with the manuscript.
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